Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Daiichi Sankyo Co Ltd Ord — FY2025 Earnings Presentation
80 slides from Daiichi Sankyo's earnings presentation, May 11, 2026
Slide 1: FY2025 Financial Results and 5-Year Business Plan Presentation & Discussion
FY2025 Financial Results and 5-Year Business Plan Presentation & Discussion (FY2026-FY2030) DAIICHI SANKYO CO., LTD. Hiroyuki Okuzawa President and CEO May 11, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward-looking statements were determined by Daiichi Sa
Slide 3: Agenda
Agenda 1 FY2025 Financial Results 2 5-Year Business Plan (FY2026-FY2030) 3 Q&A 3
Slide 4: FY2025 Financial Results Presentation
FY2025 Financial Results Presentation 4
Slide 5: Agenda
Agenda 1 FY2025 Financial Results 2 Business Update 3 R&D Update 4 FY2026 Forecast 5 Appendix 5
Slide 6: Summary
Summary FY2025 Financial Results Significant increase in consolidated revenue driven by Revenue ENHERTU® and DATROWAY® product sales growth Core • COGs ratio improved compared to FY2024 Results Operating Profit • Core operating profit increased +15.1% YoY In FY2025 Q4, temporary expenses of approx
Slide 7: Overview of FY2025 Results
Overview of FY2025 Results (Bn JPY) FY2024 FY2025 YoY Results Results Revenue 1,886.3 2,123.0 +12.6% 236.8 Cost of sales *1 415.7 441.3 25.6 SG&A expenses *1 724.8 859.6 134.8 DXd ADC profit share *2 226.2 305.6 79.4 Other SG&A expenses 498.6 554.0 55.4 R&D expenses *1 432.9 462.1 29.3 Core operatin
Slide 8: Revenue
Revenue Increased by 236.8 Bn JPY (Increased by 215.0 Bn JPY excl. forex impact) (Bn JPY) Positive Factors Negative Factors FY2024 Results FY2024 Results 1,886.3 Japan Business Datroway +12.8 Inavir -18.3 Japan Business Tarlige ＋9.7 Realized gains of unrealized gains of (incl. Innovative Pharmaceuti
Slide 9: Core Operating Profit
Core Operating Profit Increased by 47.1 Bn JPY (Increased by 32.4 Bn JPY excl. forex impact) (Bn JPY) Revenue +236.8 incl. forex impact of +21.8 FY2024 Results FY2024 Results 312.8 Revenue Cost of Sales +19.9 Revenue 236.8 Increase in expenses related to sales expansion Cost ofofSales Cost Sales 19.
Slide 10: Profit Attributable to Owners of the Company
Profit Attributable to Owners of the Company Decreased by 35.9 Bn JPY (Bn JPY) Temporary Income/Expenses -150.0 (Profit Decreased) FY2024 Results FY2025 Results YoY FY2024 Results FY2024 Results 295.8 Temporary Income 22.2 *1 22.1 *2 ‐0.1 Temporary Expenses 3.1 153.0*3 +149.9 Core Core Operating Ope
Slide 11: FY2025 Annual Dividend Forecast
FY2025 Annual Dividend Forecast Continued profit growth on Core Operating Profit basis in FY2025 Annual dividend forecast for FY2025 remains unchanged at the previously announced 78 JPY per share (up 18 JPY) 360.0 Bn JPY 312.8 Bn JPY 78 JPY Annual Dividend per share Year-end Dividend 60 JPY Inte
Slide 12: Acquisition of Own Shares (Results)
Acquisition of Own Shares (Results) Established upper limits for acquiring own shares of up to 200 billion JPY to take flexible actions based on comprehensive consideration such as share price levels and other factors Considering share price trends during the acquisition period and increased inv
Slide 13: Agenda
Agenda 1 FY2025 Financial Results 2 Business Update 3 R&D Update 4 FY2026 Forecast 5 Appendix 13
Slide 14: ENHERTU Performance
ENHERTU® Performance Maintained No.1 new patient share across major countries and regions Achieved $5 Bn* global alliance product sales and received $537.5 Mn (86.0 Bn JPY) as sales milestone FY2025 Global Product Sales Results 698.4 Bn JPY 861.3 Bn JPY YoY +145.5 Bn JPY (+26.3%) Progress vs J
Slide 15: DATROWAY Performance
DATROWAY® Performance Treated more than 4,900 patients globally since launch, approx. 1.6 times the prior quarter Robust sales growth in US and Japan; US sales mainly driven by lung cancer indication 111.4 Bn JPY FY2025 Global Product Sales Results 47.6 Bn JPY YoY +46.2 Bn JPY Progress vs Jan.
Slide 16: Agenda
Agenda 1 FY2025 Financial Results 2 Business Update 3 R&D Update 4 FY2026 Forecast 5 Appendix 16
Slide 17: ENHERTU Major Results for FY2025
ENHERTU® Major Results for FY2025 EXPAND: Go earlier and broader Generate robust data in HER2 positive breast cancer and expanding into other cancers Establishing leadership in HER2+ breast cancer Further expansion for HER2 expressing gynecological cancers DESTINY-Breast09: ENHERTU® plus pertuzuma
Slide 18: Expand ENHERTU into Early HER2+ Breast Cancer
ENHERTU® Expand ENHERTU® into Early HER2+ Breast Cancer DESTINY-Breast11 Ph3 First approval of ENHERTU® for early breast cancer in China pCR (ESMO 2025) EFS (ESMO 2025) Data cutoff: March 12, 2025 ENHERTU®- ddAC-THP THP ENHERTU®-THP ENHERTU®-THP arm showed 11.2% improvement in pCR rate compared to
Slide 19: ENHERTU Regulatory Updates
ENHERTU® Regulatory Updates Indication expansion across countries and regions Feb 2026: Post-Neoadjuvant Treatment for Patients — Filing accepted in EU — Filing accepted in Japan with HER2 Positive Early BC Mar 2026： （DESTINY-Breast05） — Filing accepted in US （PDUFA date: July 7, 2026） HER2 positive
Slide 20: DATROWAY Major Results for FY2025
DATROWAY® Major Results for FY2025 EXPAND: Establishment and expansion of TROP2-directed DXd ADC therapy in BC and LC Unlocking new growth of DATROWAY® Approval for lung cancer and utilization Expansion to new cancer types of biomarker supported by clinical data TROPION-Lung05: Accelerated approva
Slide 21: DXd ADC Major Results of FY2025
DXd ADC Major Results of FY2025 Next Wave EXTEND: beyond DXd ADCs In addition to obtaining data on I-DXd and R-DXd, clinical trials for new assets have also begun Progress in DXd ADCs following ENHERTU® and DATROWAY® Voluntarily withdrew submission of HER3-DXd for EGFR- mutated NSCLC in the US in
Slide 22: I-DXd Seeking Accelerated Approval for ES-SCLC
I-DXd Seeking Accelerated Approval for ES-SCLC IDeate-Lung01 Ph2 Application accepted in US; expected to be the first approval of I-DXd Primary endpoint:ORR（WCLC2025） I-DXd demonstrated remarkable efficacy in previously treated ES-SCLC patients (confirmed ORR among all participants receiving I-DXd
Slide 23: DS2001 New Program for Autoimmune Disease Field
DS2001 New Program for Autoimmune Disease Field Anti-ORAI1 antibody Daiichi Sankyo original immunosuppressive agent targeting ORAI1 Mechanism of Action DS2001 is an anti-ORAI1 Stimulation antibody Ca2+ DS2001 DS2001a ORAI1 is the major pore-forming ORAI1 subunit of CRAC channel in immune cells a
Slide 24: Awards from the Pharmaceutical Society of Japan
Next Wave Awards from the Pharmaceutical Society of Japan The development of DAICHIRONA® and EZHARMIA® each received awards DAICHIRONA ® , Intramuscular Injection Daiichi Sankyo vaccine team won the 2026 Pharmaceutical Society of Japan Award for Drug Research and Development for “development of a SA
Slide 25: FY2026 News Flow
FY2026 News Flow As of May 2026 Upcoming regulatory decisions Upcoming key data readouts DESTINY-Breast11: HER2 positive BC, DESTINY-Lung04: HER2 mutation NSCLC, 1L, Ph3 ENHERTU® neoadjuvant, Ph3 • FY2026 H1 • US: FY2026 H1 (PDUFA date: May 18, 2026) TROPION-Lung07: non-squamous NSCLC, w/o AGA, PD-L
Slide 26: Agenda
Agenda 1 FY2025 Financial Results 2 Business Update 3 R&D Update 4 FY2026 Forecast 5 Appendix 26
Slide 27: Change in Definition of Core Operating Profit (Effective from FY2026)
Change in Definition of Core Operating Profit (Effective from FY2026) With the adoption of IFRS 18, “Presentation and Disclosure in Financial Statements,” the presentation of the consolidated income statement is scheduled to change effective from FY2027 In anticipation of the impact of this adop
Slide 28: FY2026 Forecast
FY2026 Forecast (Bn JPY) FY2025 FY2026 vs. Results Results Forecast Revenue Revenue 2,123.0 2,280.0 157.0 ：Increase due to Market Penetration of Enhertu Datroway, especially in the U.S ：Declining sales in the iron supplement business Cost of sales *1 610.3 530.0 -80.3 Drug price revision for Lixiana
Slide 29: FY2026 Annual Dividend Forecast
FY2026 Annual Dividend Forecast Under the 5-Year Business Plan (FY26-FY30), stable dividends will be distributed based on progressive dividends and adjusted DOE * (with the target of 10.0% annually) Given the expectations for further growth under 5-Year Business Plan (FY26-FY30), increase of the
Slide 30: Agenda
Agenda 1 FY2025 Financial Results 2 Business Update 3 R&D Update 4 FY2026 Forecast 5 Appendix 30
Slide 31: Initiatives Related to Profit Growth for Current Business and Products in Japan
Initiatives Related to Profit Growth for Current Business and Products in Japan Focusing resources on innovative pharmaceuticals business Stock Transfer of DAIICHI SANKYO HEALTHCARE CO., LTD. (Concluded an agreement in April 2026) Transferee: Suntory Holdings Limited Consideration for transfer
Slide 32: Revenue: Business Units (incl. Forex Impact)
Revenue: Business Units (incl. Forex Impact) (Bn JPY) FY2024 FY2025 YoY Results Results Japan Business 476.9 485.8 +8.9 Daiichi Sankyo Healthcare 86.7 90.7 +4.1 Oncolgy Business 463.8 608.8 +145.0 Enhertu 451.6 561.1 +109.5 Datroway 1.1 34.4 +33.3 Turalio 6.6 5.2 -1.4 Vanflyta 4.5 8.2 +3.6 American
Slide 33: Revenue: Major Products in Japan
Revenue: Major Products in Japan (Bn JPY) FY2024 FY2025 YoY Results Results Lixiana anticoagulant 133.0 141.8 +8.7 Tarlige pain treatment 55.6 65.4 +9.7 Treatment for osteoporosis/ inhibitor of the progression of Pralia bone erosion associated with rheumatoid arthritis 42.2 45.8 +3.5 anti-cancer age
Slide 34: 5DXd ADCs Revenue (incl. Forex Impact)
5DXd ADCs Revenue (incl. Forex Impact) ( Bn JPY) FY2025 FY2026 YoY YoY Results Forecast ENHERTU® 819.5 +168.1 993.3 +173.8 Product Sales 698.4 +145.5 861.3 +162.9 Upfront and Milestone Payments, etc. 121.1 +22.6 132.0 +10.9 DATROWAY® 56.1 +48.2 121.5 +65.5 Product Sales 47.6 +46.2 111.4 +63.8 Upfron
Slide 35: 5DXd ADCs Upfront and Milestone Payments
5DXd ADCs Upfront and Milestone Payments (Unit: Bn JPY) FY2025 FY2026 Total Consideration Asset Item YoY YoY Results Forecast (as of Mar 2026) Upfront Payment 10.2 - 10.2 - 149.0 Regulatory Milestones 23.8 -5.5 26.9 +3.1 209.7 ® ENHERTU Quid Related Payment 1.2 - 1.2 - 17.2 Sales Milestone 86.0 +28.
Slide 36: Breakdown of Temporary Expenses for FY2025
Breakdown of Temporary Expenses for FY2025 （Bn JPY） Full-base Core basis SG&A R&D Temporary Cost of Sales Other Total expenses expenses expenses FY2025 Full-Year Results 227.7 -78.9 3.9 0.3 153.0 153.0 Temporary expenses newly incurred in 4Q 196.3 -66.2 2.8 0.3 133.2 133.2 CMO Compension fee 148.5 -
Slide 37: Impact on FY2025 Results Due to Change in Definition of Core Operating Profit
Impact on FY2025 Results Due to Change in Definition of Core Operating Profit （Bn JPY） Adjustment FY2025 Results Amortization of FY2025 Results CMO Write-down of Previous definition intangible assets New definition compensation fee inventories related to products Revenue 2,123.0 2,123.0 Cost of sale
Slide 38: Major R&D Milestones: ENHERTU
Major R&D Milestones : ENHERTU® As of May 2026 Target indication FY2025 FY2026 Project [phase, study name] H2 H1 H2 • TLR obtained • Regulatory decision • HER2+ with high risk of recurrence, • Filing accepted anticipated (US) post neo-adjuvant [Ph3, DESTINY-Breast05] (JP/US/EU) • Filing accepted (CN
Slide 39: Major R&D Milestones: DATROWAY
Major R&D Milestones : DATROWAY® As of May 2026 Target indication FY2025 FY2026 Project [phase, study name] H2 H1 H2 • non-squamous, w/o AGA, PD-L1 TPS <50%, 1L, pembrolizumab ± PBC combo • TLR anticipated [Ph3, TROPION-Lung07] • EGFR mutated, progressed on prior osimertinib, 2L+, mono or osimertini
Slide 40: Major R&D Milestones: I-DXd and Next Wave
Major R&D Milestones : I-DXd and Next Wave As of May 2026 Target indication FY2025 FY2026 Project [phase, study name] H2 H1 H2 • Regulatory decision I-DXd • ES-SCLC, 2L+ [Ph2, IDeate-Lung01] • Filing accepted (US) anticipated (US) EZHARMIA® • CRPC, darolutamide combo [Ph1] • Study started • ES-SCLC,
Slide 41: Major R&D Pipeline: 5DXd ADCs (1)
Major R&D Pipeline: 5DXd ADCs (1) As of May 2026 Phase 1 Phase 1/2 Phase 2 (US/EU/Asia) HER2 low BC (JP/US/EU/Asia) NSCLC (US/EU/Asia) HER2+ BC 2L+/1L (US/EU/Asia) in prep HER2 negative GC 1L (JP/US/EU/Asia) solid tumors (US/EU/Asia) non-squamous NSCLC 2L chemo naïve/post chemo （combo) (chemo combo)
Slide 42: Major R&D Pipeline: 5DXd ADCs (2)
Major R&D Pipeline: 5DXd ADCs (2) As of May 2026 Phase 2/3 Phase 3 Regulatory phase (JP/US/EU/Asia) UC post enfortumab (JP/US/EU/Asia) HER2+ BC 1L (JP/US/EU/Asia) HER2 expressing pMMR EC (JP/US/EU/Asia) TROP2 NMR+ (JP/US/EU/Asia) HR positive and HER2 (CN) HER2 expressing solid tumors vedotin + pembr
Slide 43: Major R&D Pipeline: Next Wave
Major R&D Pipeline: Next Wave As of May 2026 Phase 1 Phase 1/2 Phase 2 Phase 3 Regulatory phase DS-1103 (US/EU) DS-3939 (JP/US/EU/Asia) ® EZHARMIA (EU) ® VANFLYTA (JP/US/EU/Asia) ® VANFLYTA (CN) Anti-SIRPα antibody TA-MUC1-directed DXd ADC EZH1/2 inhibitor FLT3 inhibitor FLT3 inhibitor HER2 expressi
Slide 44: 5-Year Business Plan (FY2026-FY2030)
5-Year Business Plan (FY2026‒FY2030)
Slide 45: Agenda
Agenda 1 5-Year Business Plan (FY2021-FY2025) Recap 2 5-Year Business Plan (FY2026-FY2030) 45
Slide 46: Strategic Pillars of the 5-Year Business Plan (FY2021-FY2025)
Strategic Pillars of the 5-Year Business Plan (FY2021-FY2025) Realize 2025 Goal and Shift to Further Growth FY2025 Revenue: 1.6 Tn JPY (Oncology > 600.0 Bn JPY) ROE > 16% Financial Targets Core Operating Profit* Ratio before R&D Expense: 40％ DOE** > 8% Profit growth for current Identify and
Slide 47: 5-Year Business Plan (FY2021-FY2025) Recap: Maximize 3ADCs
5-Year Business Plan (FY2021-FY2025) Recap: Maximize 3ADCs The oncology business achieved significant growth, driven by ENHERTU® and DATROWAY® Entered into a strategic alliance with US MRK*, in addition to AstraZeneca Transformed SOC in HER2+ BC and established HER2 low and ultralow BC as a ne
Slide 48: Recap: Strategic Pillars and Business Foundation
5-Year Business Plan (FY2021-FY2025) Recap: 3 Strategic Pillars and Business Foundation Profit growth for Expanded sales and profit margins from specialty medicines such as LIXIANA®, TARLIGE®, and NILEMDO® current business and Declined profit margins due to intensifying competition for INJECTAFE
Slide 49: 5-Year Business Plan (FY2021-FY2025) Recap: Financial Targets
5-Year Business Plan (FY2021-FY2025) Recap: Financial Targets At the time of planning 5YBP FY2025 Revenue 1.6 Tn JPY 2.1 Tn JPY Revenue in Oncology > 600.0 Bn JPY 954.0 Bn JPY Core Operating Profit ratio before R&D 40% 38.7% ROE > 16% 15.8% DOE > 8% 8.7% Currency exchange 1 USD=105 JPY, 1 EUR=120 JP
Slide 50: 5-Year Business Plan (FY2021-FY2025) Recap: Overview
5-Year Business Plan (FY2021-FY2025) Recap: Overview 5-Year Business Plan Realizing a Global Pharma Innovator 2021-2025 (FY2021–FY2025) 第５期中計 with Competitive Advantage in Oncology 「がんに強みを持つ先進的グローバル創薬企業」を実現 Revenue Recap: FY2021 – FY2025 Bn JPY Core Operating Profit Core Operating Profit ration befo
Slide 51: Agenda
Agenda 1 5-Year Business Plan (FY2021-FY2025) Recap 2 5-Year Business Plan (FY2026-FY2030) 51
Slide 52: 2035 Vision
2035 Vision 2035 Vision Trusted healthcare innovator transforming the lives of people through our science and technology 52
Slide 53: New 5-Year Business Plan (FY2026-FY2030)
New 5-Year Business Plan (FY2026-FY2030) FY2021-FY2025 FY2026-FY2030 FY2031-FY2035 2035 Vision Trusted healthcare innovator transforming the lives of people through our science and technology — Be a Global Top 5 Oncology Company 2030 Goal — New BGTs after DXd ADCs contributing to business 2025 Goal
Slide 54: 5-Year Business Plan (FY2026-FY2030) Key Strategies
5-Year Business Plan (FY2026-FY2030) Key Strategies 2030 Goal Innovative Global Healthcare Company Contributing to the Sustainable Development of Society FY2030 Financial KPIs Operating Revenue >3.0 Tn JPY Profit >600.0 Bn JPY EPS >260 JPY Be a Global Top 5 Identify next BGTs Oncology Company by 203
Slide 55: Daiichi Sankyo as a Global Top 5 Oncology Company
Daiichi Sankyo as a Global Top 5 Oncology Company Innovation and advancement of care for patients with serious illness and bring the field of oncology one step closer to cure for patients worldwide Bringing novel treatment options focusing on personalized medicine to patients beyond the reach of
Slide 56: Strong Growth in Oncology over the Past Five Years
Strong Growth in Oncology over the Past Five Years Daiichi Sankyo oncology business expanded largely through the strategic alliances over the past five years; our medicines treated more than 240k patients Business expansion achieved through product launches, indication expansions and reimburseme
Slide 57: Daiichi Sankyo in 2030
Daiichi Sankyo in 2030 Continued revenue growth will be led by ENHERTU® and DATROWAY® during next 5-Year Business Plan, with target of 2.3 Tn JPY in oncology revenue by 2030 Establish stand-alone capability to maximize product value by having competitive pipeline to realize sustainable growth 2.
Slide 58: Building Capabilities to Be a Global Top 5 Oncology Company
Building Capabilities to Be a Global Top 5 Oncology Company Build and strength robust stand-alone clinical development and commercial capabilities for future profit generation by leveraging experience and learning from strategic alliances in oncology R&D Excellence Business Excellence Enhance laun
Slide 59: Continue to Build Clinical Development Capability
Continue to Build Clinical Development Capability as a Global Top 5 Oncology Company Accelerate Clinical Development Speed Realize global standard clinical development speed Achieved the fastest level in the world from FSD to the first launch in ENHERTU® in 4 years 3 months Aim to achieve a co
Slide 60: More than 20 pivotal studies data readouts expected in the next five years
More than 20 pivotal studies data readouts expected in the next five years Increase patient access to medicine with timely launches and new indications globally through rapid market penetration Secure long-term product value through pricing/reimbursement strategy, and data/evidence generation FY
Slide 61: More than 20 pivotal studies data readouts expected in the next five years
More than 20 pivotal studies data readouts expected in the next five years $2 Bn - $6 Bn total peak year sales potential readouts continuing every year for the next five years FY2026 FY2027 FY2028+ Expected Data Readouts Expected Data Readouts Expected Data Readouts • DESTINY-Lung04 • TROPION-Brea
Slide 62: Leading in Breast and Lung Cancer
Leading in Breast and Lung Cancer Maintain and expand leadership in breast cancer through life cycle management of ENHERTU® and DATROWAY® Establish leadership in lung cancer with biomarker research and development Major Studies in Breast Cancer Major Studies in Lung Cancer • Pivotal studies and
Slide 63: Be a Global Top 5 Oncology Company by 2035
Be a Global Top 5 Oncology Company by 2035 DXd ADC technology anticipated to generate more than 3 Tn JPY peak sales through life cycle management including indication expansions; following DXd ADCs also have blockbuster potential Daiichi Sankyo will be a Global Top 5 Oncology Company by 2035 and
Slide 64: What is BGT?
What is BGT? Breakthrough Generating Technology BGT: Daiichi Sankyo’s proprietary innovative technology to deliver more innovative medicines to patients faster BGT Platform: “Daiichi Sankyo’s proprietary technology” × “Research and development for multiple diseases” Generate multiple drug candidat
Slide 65: Emerging BGT Candidate Modalities Driving ADC Innovation
Emerging BGT Candidate Modalities Driving ADC Innovation Novel cytotoxic payloads to IO payloads for durable overcome DXd ADC resistance remission — Leverage clinical insights as a leading Topo I inhibitor — Activate the immune system via the STING pathway innovator to develop next-generation payloa
Slide 66: Emerging BGT Candidate Modalities from Multi-Modality Research
Emerging BGT Candidate Modalities from Multi-Modality Research Advancement in antibody High-value chemical engineering: Multi-specific antibody modality: TPD molecule — Leverage advanced antibody engineering technologies — Degrade target proteins, enabling access to previously including T cell engag
Slide 67: Breakthrough Asset Candidates in Immuno-Oncology
Breakthrough Asset Candidates in Immuno-Oncology Our IO assets cover multiple key mechanisms of cancer immunology Treg depletion Don’t eat me signal inhibition Undisclosed assets DS-1103 (Ph1) APC activation DS3610 (Ph1) T cell induction DS-2243 (Ph1) Gocatamig (Ph1/2) Neo-antigen • Clinical signa
Slide 68: Stronger Pipeline Potential Built by Next BGTs
Stronger Pipeline Potential Built by Next BGTs Unlocking greater business potential through BGTs following DXd ADC The 1st BGT: Next BGTs DXd ADC Breakthrough assets >$20B Business potential with 7 assets Cytotoxic Engineered Submission-enabling readouts in IO ADC ADC >20 ADC next 5 years >5 Ongoi
Slide 69: Expanding Drug Discovery Research Capabilities
Expanding Drug Discovery Research Capabilities: Creation of BGTs through the integration of expanded research functions, digital transformation (DX) of drug discovery research, and open innovation FY2020 FY2025 FY2030 Dramatic expansion of research facilities Further Development Strengthening ta
Slide 70: Science & Technology, Demonstrated by Progress of Out-Licensed Products
Daiichi Sankyo’s Science & Technology, Demonstrated by the Progress of Out-Licensed Products Out-licensed innovative drugs originated from our labs are now reaching patients Milestone/running royalties are expected based on the agreements Out-licensed clinical assets DS-6051 (taletrectinib), ROS
Slide 71: Operational Excellence to Enhance Profit Generation
Operational Excellence to Enhance Profit Generation Optimize the cost structure to enhance profit generation Establish a Business Transformation function to drive company-wide Operational Excellence Significantly enhance productivity Optimize the procurement and through AI and digital technologi
Slide 72: Operational Excellence to Enhance Profit Generation
Operational Excellence to Enhance Profit Generation Establish a new organization and appoint a Chief Commercialization Officer to centrally manage all global commercialization activities in FY2027 Execute activities with greater speed and consistency worldwide Optimize commercialization resource
Slide 73: Initiatives toward Be a trusted partner for sustainable society
Initiatives toward “Be a trusted partner for sustainable society” あ Improving PAP Foster Patient Centricity Providing employees opportunities to understand patients’ perspectives and experiences Ethically contribute to Deliver added value through continuous data and evidence generation medica
Slide 74: Cash Allocation (FY2026-FY2030)
Cash Allocation (FY2026-FY2030) Well-Balanced Investment for Growth and Shareholder Returns Capital Allocation Resources R&D Approx. 2.9 Tn JPY Investment for growth Operating CF Expense Before R&D expenses during 5-Year Business Plan CAPEX Approx. 0.7 Tn JPY Approx. Strategic Investment for sustain
Slide 75: Shareholder Return Policy
Shareholder Return Policy Stable dividend: Progressive dividends and adjusted DOE* >10.0% (annually) Share buyback: Prioritize investment for growth and progressive dividends. Flexible buyback will be considered. Image of annual dividend 100 JPY 78 JPY 60 JPY 50 JPY 27JPY 30 JPY FY2021 Results F
Slide 76: FY2030 Financial KPIs and Looking Ahead to FY2035
FY2030 Financial KPIs and Looking Ahead to FY2035 While gradually increasing investment in R&D as a source of mid to long-term growth, build a robust foundation for profit growth in FY2026 to FY2029 and sharply accelerate profit growth in FY2030 Positioned to achieve operating profit on the scal
Slide 77: Highlights of the 5-Year Business Plan (FY2026-FY2030)
Highlights of the 5-Year Business Plan (FY2026-FY2030) Realize profit growth toward 2030 driven by DXd ADCs sales expansion and operational excellence Identify new BGTs beyond DXd ADCs to achieve sustainable growth Positioned to achieve operating profit on the scale of 1.0 Tn JPY in early 2030s F
Slide 78: Daiichi Sankyo will contribute to the enrichment of quality of life around the world
Daiichi Sankyo will contribute to the enrichment of quality of life around the world 78
Slide 79: Q&A
Q&A Hiroyuki Okuzawa John Tsai President and CEO Head of Global R&D Tomohiro Kodama Yuki Abe CFO Head of R&D Division Ken Keller Head of Global Oncology Business
Slide 80: Contact
Contact Daiichi Sankyo Co., Ltd. Investor Relations and Shareholder Relations Department Email: DaiichiSankyoIR_jp@daiichisankyo.com
Daiichi Sankyo Co Ltd Ord — FY2025 Earnings Presentation on 6ix